Tissue Disposition of 2′-O-(2-methoxy) ethyl Modified Antisense Oligonucleotides in Monkeys

Journal of Pharmaceutical Sciences

Volumn 93, Issue 1, 2004, Pages 48-59

  Yu, Rosie Z ^a   Geary, Richard S ^a   Monteith, David K ^a   Matson, John ^a   Truong, Loanne ^a   Fitchett, Jon ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Capillary gel electrophoresis; Metabolism; Monkey; Pharmacokinetics; Second generation antisense oligonucleotide

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; NUCLEASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ELIMINATION; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MONKEY; NONHUMAN; PLASMA CLEARANCE; PROTEIN BINDING; REDUCTION; TISSUE DISTRIBUTION; URINARY EXCRETION;

EID: 0347124829     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10473     Document Type: Article

References (33)

1. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM. 1992. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267:19954-19962.
2. Bennett CF, Dean N, Ecker DJ, Monia BP. 1996. Pharmacology of antisense therapeutic agents - Cancer and inflammation. In: Agrawal S, editor. Methods in molecular medicine: Antisense therapeutics. Totowa, NJ: Humana Press Inc.
3. Cowsert LM. 1997. In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development. Anticancer Drug Des 12:359-371.
4. Altmann K-H, Dean NM, Fabbro D, Freier SM, Geiger T, Haner R, Husken D, Martin P, Monia BP, Muller M, Natt F, Nicklin P, Phillips J, Pieles U, Sasmor H, Moser HE. 1996. Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chimia 50:168-176.
5. Freier SM, Lima WF, Sanghvi YS, Vickers T, Zounes M, Cook PD, Ecker DJ. 1992. Thermodynamics of antisense oligonucleotide hybridization. In: Erickson RP, Izant JG, editors. Gene regulation: Biology of antisense RNA and DNA. New York: Raven Press, Ltd.
6. Matteucci M. 1996. Structural modifications toward improved antisense oligonucleotides. Perspect Drug Discov Des 4:1-16.
7. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, Griffey RH. 1996. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277:923-937.
8. Cummins LL, Owens SR, Risen LM, Lesnik EA, Freier SM, McGee D, Guinosso CJ, Cook PD. 1995. Characterization of fully T-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res 23:2019-2024.
9. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S. 1996. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 51:173-182.
10. Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke ST. 1993. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181-1190.
11. Agrawal S, Temsamani J, Galbraith W, Tang J. 1995. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28:7-16.
12. Geary RS, Leeds JM, Fitchett J, Burckin T, Troung L, Spainhour C, Creek M, Levin AA. 1997. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 25:1272-1281.
13. Phillips JA, Craig SJ, Bayley D, Christian RA, Geary RS, Nicklin PL. 1997. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54:657-668.
14. Grindel JM, Musick TJ, Jiang Z, Roskey A, Agrawal S. 1998. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev 8:43-52.
15. Yu RZ, Geary RS, Leeds JM, Ushiro-Watanabe T, Fitchett JR, Matson JE, Mehta R, Hardee GR, Templin MV, Huang K, Newman MS, Quinn Y, Uster P, Zhu G, Working PK, Horner M, Nelson J, Levin AA. 1999. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-Ras encapsulated in stealth liposomes. Pharm Res 16:1309-1315.
16. Agrawal S, Temsamani J, Tang JY. 1991. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595-7599.
17. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary RS, Dorr FA, Von Hoff D, Eckhardt SG. 1999. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase c-alpha, in patients with advanced cancer. J Clin Oncol 17:3586-3595.
18. Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ. 1999. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 17:2227-2236.
19. Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR Jr. 1997. Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 282:1173-1180.
20. Geary RS, Watanabe TA, Truong L, Freier SM, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA. 2001. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897.
21. Cummins LL, Greig M, Griffey RH, Gaus HJ. 1997. The role of HPCE and mass spectrometry in pharmacokinetic and metabolic studies of first and second generation antisense oligonucleotides. Book of Abstracts, 213th ACS National Meeting, San Francisco, April 13-17.
22. Zhou W, Agrawal S. 1998. Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg Med Chem Lett 8:3269-3274.
23. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. 1997. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA 94:2620-2625.
24. Geary RS, Leeds JM, Henry SP, Monteith D, Levin AA. 1997. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Design 12:383-393.
25. Geary RS, Leeds JM, Henry SP, Glover J, Shanahan W, Fitchett J, Burckin T, Troung L, Levin AA. 1997. Pharmacokinetic properties of phosphorothioate oligonucleotides. Nucleosides Nucleotides 16:1689-1693.
26. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, Bennett CF. 1997. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 272:11994-12000.
27. Leeds JM, Graham MJ, Troung L, Cummins LL. 1996. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235: 36-43.
28. Gaus HJ, Owens SR, Winniman M, Cooper S, Cummins LL. 1997. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 69:313-319.
29. Griffey RH, Greig MJ, Gaus HJ, Liu K, Monteith D, Winniman M, Cummins LL. 1997. Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrople ion trap mass spectrometer. J Mass Spectrom 32:305-313.
30. Temsamani J, Roskey A, Chaix C, Agrawal S. 1997. In vivo metabolic profile of a phosphorothioate oligodeoxynucleotide. Antisense Nucleic Acid Drug Dev 7:159-165.
31. Cohen AS, Bourque AJ, Wang BH, Smisek DL, Belenky A. 1997. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev 7:13-22.
32. Geary RS, Matson J, Levin AA. 1999. A nonradioisotape biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal Biochem 274:241-248.
33. Yu RZ, Geary RS, Leeds JM, Ushiro-Watanabe T, Moore M, Fitchett J, Matson J, Burckin T, Templin MV, Levin AA. 2001. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 90:182-193.